ES2667798T3 - Compuesto heterocíclico sustituido con halógeno - Google Patents

Compuesto heterocíclico sustituido con halógeno Download PDF

Info

Publication number
ES2667798T3
ES2667798T3 ES13868493.1T ES13868493T ES2667798T3 ES 2667798 T3 ES2667798 T3 ES 2667798T3 ES 13868493 T ES13868493 T ES 13868493T ES 2667798 T3 ES2667798 T3 ES 2667798T3
Authority
ES
Spain
Prior art keywords
amino
carbonyl
biphenyl
thiophene
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13868493.1T
Other languages
English (en)
Spanish (es)
Inventor
Noriaki Iwase
Hiroshi Nishida
Makoto Okudo
Masaaki Ito
Shigeyuki Kono
Masaaki MATOYAMA
Shigeru Ushiyama
Eiji Okanari
Hirofumi Matsunaga
Kenji Nishikawa
Tomio Kimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ube Corp
Original Assignee
Ube Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Industries Ltd filed Critical Ube Industries Ltd
Application granted granted Critical
Publication of ES2667798T3 publication Critical patent/ES2667798T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/36Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
ES13868493.1T 2012-12-28 2013-12-27 Compuesto heterocíclico sustituido con halógeno Active ES2667798T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2012286425 2012-12-28
JP2012286425 2012-12-28
JP2013097171 2013-05-02
JP2013097171 2013-05-02
PCT/JP2013/085277 WO2014104372A1 (ja) 2012-12-28 2013-12-27 ハロゲン置換へテロ環化合物

Publications (1)

Publication Number Publication Date
ES2667798T3 true ES2667798T3 (es) 2018-05-14

Family

ID=51021433

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13868493.1T Active ES2667798T3 (es) 2012-12-28 2013-12-27 Compuesto heterocíclico sustituido con halógeno
ES18157384T Active ES2825031T3 (es) 2012-12-28 2013-12-27 Compuesto heterocíclico sustituido con halógeno útil para el tratamiento de enfermedades causadas por LPA

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES18157384T Active ES2825031T3 (es) 2012-12-28 2013-12-27 Compuesto heterocíclico sustituido con halógeno útil para el tratamiento de enfermedades causadas por LPA

Country Status (13)

Country Link
US (2) US10000463B2 (https=)
EP (2) EP2940013B1 (https=)
JP (3) JP6176258B2 (https=)
KR (1) KR102189166B1 (https=)
CN (2) CN104884447B (https=)
AU (1) AU2013366898B2 (https=)
BR (1) BR112015015275B1 (https=)
CA (1) CA2896701C (https=)
DK (2) DK3360869T3 (https=)
ES (2) ES2667798T3 (https=)
MX (1) MX369801B (https=)
RU (2) RU2756506C2 (https=)
WO (1) WO2014104372A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102189166B1 (ko) * 2012-12-28 2020-12-09 우베 고산 가부시키가이샤 할로겐 치환 헤테로환 화합물
WO2014145873A2 (en) 2013-03-15 2014-09-18 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
JP2014231508A (ja) * 2013-05-02 2014-12-11 宇部興産株式会社 ハロゲン置換へテロ環化合物
RU2689315C2 (ru) * 2014-06-27 2019-05-27 Убе Индастриз, Лтд. Соль гетероциклического соединения, замещенного галогеном
EP3378491A4 (en) * 2015-11-20 2019-07-17 UBE Industries, Ltd. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF NASH
PH12022550225A1 (en) 2019-07-30 2022-12-19 Taisho Pharmaceutical Co Ltd Urea compound for antagonizing lpa1 receptor
EP4058144A1 (en) 2019-11-15 2022-09-21 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
EP4161936A1 (en) 2020-06-03 2023-04-12 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
CN111909170B (zh) * 2020-09-11 2022-08-12 吉林奥来德光电材料股份有限公司 一种有机电致发光化合物、其制备方法以及包含该有机电致发光化合物的有机电致发光器件
JP2022115836A (ja) * 2021-01-28 2022-08-09 大正製薬株式会社 Lpa1受容体を拮抗するウレア化合物を有効成分として含有する医薬
WO2022240879A1 (en) 2021-05-11 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
WO2023107938A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
US12180414B2 (en) 2022-12-12 2024-12-31 Bmic Llc Downstream uses for briquettes and other forms of powder from asphalt shingle waste

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1258484E (pt) * 2000-02-18 2009-04-03 Kyowa Hakko Kirin Co Ltd Novos compostos de isoxazol e de tiazol e sua utilização enquanto fármacos
WO2002062389A1 (en) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
JP4692281B2 (ja) * 2003-08-05 2011-06-01 味の素株式会社 新規アゾール化合物
CA2738878C (en) 2008-09-29 2013-08-13 Eli Lilly And Company Selective estrogen receptor modulator for the treatment of osteoarthritis
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
CN102574822A (zh) 2009-08-04 2012-07-11 阿米拉制药公司 作为溶血磷脂酸受体拮抗剂的化合物
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
WO2011091167A2 (en) 2010-01-22 2011-07-28 The General Hospital Corporation Lysophosphatidic acid receptor targeting for scleroderma and other fibrotic diseases
WO2011159635A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions
WO2011159633A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
WO2011159632A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
KR20130126659A (ko) * 2010-12-07 2013-11-20 아미라 파마슈티칼스 인코포레이티드 리소포스파티드산 수용체 길항제 및 섬유증 치료에서의 그의 용도
DK2648726T3 (da) 2010-12-07 2018-07-16 Amira Pharmaceuticals Inc Polycyklisk lpa1-antagonist og anvendelser deraf
WO2012138797A1 (en) * 2011-04-05 2012-10-11 Amira Pharmaceuticals, Inc. 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
JP2014525932A (ja) 2011-08-15 2014-10-02 インターミューン, インコーポレイテッド リゾホスファチド酸レセプターアンタゴニスト
KR102189166B1 (ko) * 2012-12-28 2020-12-09 우베 고산 가부시키가이샤 할로겐 치환 헤테로환 화합물

Also Published As

Publication number Publication date
EP2940013A4 (en) 2016-08-03
JP6414286B2 (ja) 2018-10-31
EP3360869A1 (en) 2018-08-15
US10000463B2 (en) 2018-06-19
RU2018109925A (ru) 2019-02-27
JP2017214410A (ja) 2017-12-07
US10597375B2 (en) 2020-03-24
JP6176258B2 (ja) 2017-08-09
EP2940013B1 (en) 2018-02-21
BR112015015275A8 (pt) 2019-10-22
JP6569792B2 (ja) 2019-09-04
AU2013366898A1 (en) 2015-08-13
WO2014104372A1 (ja) 2014-07-03
ES2825031T3 (es) 2021-05-14
MX369801B (es) 2019-11-21
DK3360869T3 (da) 2020-10-12
AU2013366898B2 (en) 2017-06-29
RU2015131139A (ru) 2017-02-03
EP2940013A1 (en) 2015-11-04
DK2940013T3 (en) 2018-03-26
KR102189166B1 (ko) 2020-12-09
CA2896701A1 (en) 2014-07-03
RU2756506C2 (ru) 2021-10-01
CN107698555B (zh) 2020-05-05
EP3360869B1 (en) 2020-07-29
JPWO2014104372A1 (ja) 2017-01-19
CN104884447A (zh) 2015-09-02
JP2019014739A (ja) 2019-01-31
CN107698555A (zh) 2018-02-16
BR112015015275A2 (pt) 2017-07-11
BR112015015275B1 (pt) 2021-12-14
RU2018109925A3 (https=) 2020-12-03
CA2896701C (en) 2020-10-06
KR20150100756A (ko) 2015-09-02
US20150376160A1 (en) 2015-12-31
US20180258062A1 (en) 2018-09-13
RU2649398C2 (ru) 2018-04-03
CN104884447B (zh) 2017-10-10
MX2015008479A (es) 2015-09-23

Similar Documents

Publication Publication Date Title
ES2667798T3 (es) Compuesto heterocíclico sustituido con halógeno
US10150728B2 (en) Alkylene derivatives
ES2474490T3 (es) Derivados de triazina como antagonistas de receptores P2X3 y/o P2X2/3 y composición farmacéutica que los contiene
KR102814881B1 (ko) 비전신성 tgr5 작용제로서의 치환된 4-페닐 피리딘 화합물
US9655897B2 (en) Heterocyclyl pyrimidine analogues as TYK2 inhibitors
US20100278733A1 (en) Composition for diagnosis of amyloid-related disease
US20110212969A1 (en) Substituted hydroxamic acids and uses thereof
US20130310379A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
US10640495B2 (en) Heterocycle derivatives having TrkA inhibitory activity
US6670367B1 (en) Azinyloxy, and phenoxy-diaryl-carboxylic acid derivatives, their preparation and use as mixed ETA/ETB endothelin receptor antagonists
US12545687B2 (en) Uracil derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same
US6440975B1 (en) Amino acid derivatives, the preparation and use thereof as endothelin antagonists
US20150246938A1 (en) Novel olefin derivative
WO2023051261A1 (zh) 一种亚胺类化合物及其应用
US12528790B2 (en) Amide derivative having antiviral activity
US6448248B1 (en) Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists
US20100003191A1 (en) Aurone derivative-containing composition for diagnosis
US20170253607A1 (en) Long-acting hiv protease inhibitor
CN1261352A (zh) 新的β-氨基和β-叠氮基羧酸衍生物、其制备及其作为内皮素受体拮抗剂的应用
US6358983B1 (en) Heterocyclically substituted α-hydroxycarboxylic acid derivatives, method for producing the same and their use as endothelin receptor antagonists
US20260125392A1 (en) Uracil derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same
HK1026417A (en) Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists